血浆MicroRNA-17-5p和microRNA-20水平与肺动脉高压预后的相关性研究

doi:10.3969/j.issn.1006-6233.2017.08.002

Abstract
Figure/Table
References
Related Citation (4)

Download: PDF (1873 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To investigate the correlation between the level of plasma MicroRNA-17-5p and microRNA-20 and the severity and prognosis of pulmonary arterial hypertension (PAH). Methods: A microarray screen was performed on total plasma RNA from 112 patients with PAH and 100 healthy control subjects Quantitative polymerase chain reaction commend increased microRNA-17-5p and microRNA-20a concentrations and was then used to measure microRNA-17-5p and microRNA-20a levels in cohort of patients with PAH's circulating microvesicles and blood cells. Results: Fifty-eight miRNAs showed differences in plasma concentration. MicroRNA-17-5p and microRNA-20a are the largest up-regulation in PAH. Receiver-operator-characteristic analysis showed both raw and normalized plasma microRNA-17-5p and microRNA-20a levels correlated with 2-year survival in patients with PAH. Cox regression analysis confirmed that miRNA-17-5p and miRNA-20a levels were important predictors of PAH survival. Age, baseline cardiac index, World Health Organization functional class, 6-minute walk distance, disease duration, and red cell distribution width also predicted survival. Entering these covariates in a multivariable model veried plasma microRNA-17-5p and microRNA-20a levels as independent predictoras of survival in PAH. Conclusion: Increased circulating microRNA-17-5p and microRNA-20a levels are associated with poor survival in PAH. 

Key words： miRNA-17-5p miRNA-20a Pulmonary arterial hypertension

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2017.08.002 OR http://www.hbyxzzs.cn/EN/Y2017/V23/I8/1236

[1] Chandra SM, Razavi H, Kim J,et al . Disruption of the Apelin-APJ system worsens hypoxia-induced pulmonary hypertension[J].Arterioscl Throm Vas, 2011, 31(5): 814~821.
[2] Kim J. Apelin-APJ Signaling: a potential therapeutic target for pulmonary arterial hypertension[J].Mol Cells, 2014,37(5): 196~201.
[3] Courboulin A, Paulin R, Giguere NJ, et al. Role for miR-204 in human pulmonary arterial hypertension[J].Exp Med, 2011,211(9):535~548.
[4] Brock M, Trenkmann M, Gay RE, et al. Interleukin-6 modulates the expression of the bone morphogenic protein receptor type Ⅱ through a novel STAT3-microRNA cluster 17/92 pathway[J].Circ Res, 2009,104(10):1184~1191.
[5] Mclaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association[J].Circulation, 2009,119(6):2250~2294.
[6] Davis BN, Hilyard AC, Lagna G, et al. SMAD proteins control DROSHA-mediated microRNA maturation[J].Nature, 2008,454(6):56~61.
[7] Caruso P, Maclean MR, Khanin R, et al. Dynamic changes in lung microRNA process during the development of pulmonary hypertension due to chronic hypoxia and monocrotaline[J].Arterioscler Thromb Vasc Biol ,2010,30(7):716~723.
[8] Parikh VN, Jin RC, Rabello S, et al. MicroRNA-21 integrates pathogenic signaling to control pulmonary hypertension: results of a network bioinformatics approach[J].Circulation, 2012, 125(8):1520~1532.
[9] Hogan BL. Bone morphogenetic proteins: multi-functional regulators of vertebrate development[J].Genes Dev, 2015,10(7): 1580~1594.
[10] Machado RD, Aldred M A, James V, et al . Mutations of the TGF-beta type Ⅱ receptor BMPR2 in pulmonary arterial hypertension[J].Hum Mutat, 2016, 27(8):121~132.
[11] Brock M, Trenkmann M, Gay R E,et al. Interleukin-6 modulates the expression of the bone morphogenic protein receptor type Ⅱ through a novel STAT3-microRNA cluster 17/92 pathway[J].Circ Res, 2015, 104(8):1184~1191.
[12] Pullamsetti SS, Doebele C, Fischer A, et al. Inhibition of microRNA-17 improves lung and heart function in experimental pulmonary hypertension[J].Am Respir Crit Care Med, 2013,185(7): 409~419.
[13] Brock M, Samillan VJ, Trenkmann M, et al. Antagomir directed against miR-20a restores functional BMPR2 signalling and prevents vascular remodelling in hypoxia-induced pulmonary hypertension[J].Eur Heart, 2012, 12(4):60~70.
[14] Zaidi SH, You XM, Ciura S, et al. Overexpression of the serine elastase inhibitor elafin protects transgenic mice from hypoxic pulmonary hypertension[J].Circulation ,2002,105(9):516~521.
[15] Takahashi H, Goto N, Kojima Y, et al. Down regulation of type Ⅱ bone morphogenetic protein receptor in hypoxic pulmonary hypertension[J].Am Physiol Lung Cell Mol Physiol, 2006,290(8):450~458.